Surmodics (SRDX)
(Delayed Data from NSDQ)
$36.03 USD
+0.13 (0.36%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $36.04 +0.01 (0.03%) 7:58 PM ET
5-Strong Sell of 5 5
F Value A Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Surmodics, Inc. has a PEG ratio of 19.67 compared to the Medical - Products industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SRDX 36.03 +0.13(0.36%)
Will SRDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRDX
QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?
SRDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Options Traders Betting on a Big Move in Surmodics Stock?
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say
Other News for SRDX
Surmodics (SRDX) Stock Drops Amid FTC Deadline Extension Request
Surmodics falls as parties, FTC ask for extension of briefing schedule
Noteworthy Monday Option Activity: SRDX, CR, SPOT
Surmodics (SRDX) Shares Climb 12% Amid FTC Pre-Trial Hearing
Surmodics jumps amid pre-trial hearing in FTC's suit to block sale to GTCR